IndexIQ Advisors’s Arcturus Therapeutics ARCT Stock Holding History

IndexIQ Advisors’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$382K	Buy	+14,183	New	+$362K	0.01%	891

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IndexIQ Advisors's ARCT Position: Q1 2022 in Review

IndexIQ Advisors opened a new position in Arcturus Therapeutics (ARCT) in Q1 2022: 14,183 shares worth $382K. The stake represents 0.01% of the portfolio and ranks #891 among its holdings.

130 funds tracked by Wall St. Rank hold ARCT as of Q1 2022.

IndexIQ Advisors held 14,183 shares of Arcturus Therapeutics worth $382K as of Q1 2022.
Arcturus Therapeutics was a new IndexIQ Advisors position in Q1 2022.
Arcturus Therapeutics made up 0.01% of IndexIQ Advisors's portfolio in Q1 2022, its #891 holding.
130 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.